Avalo Therapeutics CMO Mittie Doyle sells $13,580 in stock
At a glance
- $AVTX today−5.02%last $7.00
- Vs industry peers−4.19 pts6-peer median −0.83% · far behind
- Since Aug 15−64.9%from the first trade after the story
- 52-week range7.2% above low$6.53 – $24.27
- In the headline$13,580Amount
- Coverage0 this week1 in 30 days · too few stories to call a pace
- Legal: Filed with SEC
- Clear: key person, regulatory, security, operational, financial integrity
Early signals (1) — filed with the SEC or first reported, not yet widely covered
- Legal · SEC 8-K, Item 1.02, Nov 5: Filed: the termination of a material agreement. View filing →
Close-to-close moves; beta-adjusted against the S&P 500, σ in the stock’s own daily noise; ranges one standard deviation. Reports are outlets’ words or SEC filings. Not a forecast or advice.
What it means
- What to watch: The headline hangs on one number ($13,580) — one data point is a snapshot, so the trailing trend is the context it needs.
- How the stock is trading: $AVTX -5.02% in the latest session.
- Timing: It came out on a weekend, so the change shown is Friday's and Monday's open is the first chance to trade on it. Market holidays are not detected.
Where the stock stands
Avalo Therapeutics ($AVTX) fell 5.02% to $7.00 in the latest session. Over the past month it is down 39.6%. It now sits 71% under the 52-week high of $24.27 and 7.2% above the year's low of $6.53, close to the bottom of its range. The year's high was 3.7 times its low, which makes double-digit swings fairly routine here.
How much coverage it is getting
This story is more than a month old. Since then Wook has filed one newer story on Avalo Therapeutics in the last 30 days. It reads neutral.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. Wook's supply-chain scanner shows no unusual stress in Health Care today.
What to watch next
The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $AVTX page, and they say what management has disclosed without a reporter in between. Where several outlets agree is usually the news; where they differ is the angle. To run the numbers yourself, ask Wook AI above about $AVTX: its distance from the high, its last report, or how coverage has changed.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on August 15, 2026. $AVTX has moved -64.91% ($19.95 to $7.00). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
